MAPT and Alzheimer disease: Both in vitro and in vivo studies demonstrate that upregulation of GSK-3β induces AD-like hyperphosphorylation of microtubule-associated protein tau and causes memory deficit, while inhibition of GSK-3 attenuates tau hyperphosphorylation with improvement of cognitive synaptic functions5–10.